SCHEMBL370240

SCHEMBL370240

CNc1nc(-c2cccc(NC(=O)c3cccc(C(=O)OC(C)C)c3)c2)c2cc(OC)c(OC)cc2n1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.76
PDE4B Q07343 1/20 0.76
PDE4C Q08493 1/20 0.76
PDE4D Q08499 1/20 0.76
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
HTT P42858 1/20 0.47
MAPK14 Q16539 2/20 0.42
EGFR P00533 1/20 0.42
LCK P06239 1/20 0.42
ALDH1A1 P00352 1/20 0.41
CTNNB1 P35222 1/20 0.41
TCF7L2 Q9NQB0 1/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
POLB P06746 5/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12513345 0.94 PDE4A (0.86) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL12513023 0.93 PDE4A (0.88) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL12513326 0.93 PDE4A (0.65) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL12621398 0.92 PDE4A (0.64) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL295669 0.91 PDE4A (0.75) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL296482 0.90 PDE4A (0.79) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL371380 0.89 PDE4A (0.78) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL12654371 0.89 PDE4A (0.75) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL296765 0.88 PDE4A (0.85) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL296288 0.88 PDE4A (0.73) PDE4APDE4BPDE4CPDE4DSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513269-B2 Preparation for external use EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-08-20 US disclosed
EP-2202229-B1 NOVEL PREPARATION FOR EXTERNAL USE EISAI R&D MAN CO LTD (JP) 2012-03-14 EP disclosed
US-7939540-B2 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-10 US disclosed
US-20110021545-A1 NOVEL PREPARATION FOR EXTERNAL USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-01-27 US disclosed
EP-1992622-A1 4-(3-BENZOYLAMINOPHENYL)-6,7-DIMETHOXY-2- METHYLAMINOQUINAZOLINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-11-19 EP disclosed
US-20070299094-A1 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives EISAI R&D MANAGEMENT CO., LTD. 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299094-A1 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives ITCH, HRH4, HRH1 PDE4A 1280/4885PDE4B 1378/4885PDE4C 2057/4885
US-20110021545-A1 NOVEL PREPARATION FOR EXTERNAL USE SLC26A4, SLC6A15, SLC6A19 PDE4A 3486/4885PDE4B 3375/4885PDE4C 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.